摘要
目前诊断阿尔兹海默病（Alzheimer’s disease，AD）主要依靠临床标准。这一领域极度缺乏生物学标志物来辅助诊断AD以及验证治疗效果。作为AD生物学标志物需要满足几项基本要求，包括能够反映AD的病理学特点以及拥有80％敏感性以区分于其它痴呆症，另外需可靠性和可重复性，易于操作和分析，相对便宜。在AD的发病机制中BACE1（beta-site APP—cleaving enzyme 1）是关键酶。那么是否可以通过测定外周的BACE1的水平和β-分泌酶活力做为AD的生物学标志物，其效果与直接检测大脑和脑脊液中的BACE1相等同。然而，是否外周的BACE1参与了AD病理改变以及能否反映出AD的病变进程知之甚少。本文根据国外最新有关文献，就BACE1在不同组织中作为AD的分子生物学标志物的可行性进行了阐述。
The diagnosis of Alzheimer＇ s disease （AD） relies principally on clinical criteria. As a biomarker the sample must adhere to certain basic requirements, including the ability to reflect AD pathology and differentiate it from other dementia with an 80% sensitivity. Beta - site APP - cleaving enzymel （ BACE1 ） is crucial enzymes in the pathogenesis of AD. It is unknown whether the effect of measuring the level of peripheral BACE1 and β - secretase activity as biomarkers of AD is the same as the level of BACE1 measured in the brain and CSF. This paper reviews the development of BACE1 as a biomarker for AD in different tissues.
出处
《国际老年医学杂志》
2013年第1期39-41,共3页
International Journal of Geriatrics
关键词
阿尔兹海默症
BACE1
生物学标志物
Alzheimer＇ s disease
Bata - site APP - cleaving enzymei
Biomarker
